Article

Differential retention of α-vitamin E is correlated with its transporter gene expression and growth inhibition efficacy in prostate cancer cells

Department of Urology and Pathology, University of Rochester, Rochester, New York 14642, USA.
The Prostate (Impact Factor: 3.57). 04/2007; 67(5):463-71. DOI: 10.1002/pros.20517
Source: PubMed

ABSTRACT

Epidemiological studies showed Vit E has protective effects against prostate cancer (PCa). Interestingly, different prostate cancer cells have different sensitivity to alpha-Vit E or VES treatment. The goal of this study is to determine whether cellular Vit E bioavailability and its transport proteins are important contributing factors.
alpha-Vit E and its ester form, VES, were used to treat prostate cancer LNCaP, PC3, and DU145 cells, and their growth rates were determined by MTT assay. Cellular levels of Vit E were quantified using HPLC as the index of bioavailability. The expression levels of Vit E transport proteins were determined by real-time PCR.
Among these PCa cells, only LNCaP cells were sensitive to 20 microM alpha-Vit E treatment, while both LNCaP and PC3 cells were sensitive to 20 microM VES treatment. Coordinately, cellular levels of alpha-Vit E and VES positively correlated to their inhibitory effects. Further study found expression levels of Vit E transport proteins, including tocopherol associated protein (TAP), scavenger receptor class B type I (SR-BI), alpha-tocopherol transfer protein (TTP), and ATP binding cassette transporter A1 (ABCA1), were different in various PCa cells, which may contribute to cellular Vit E bioavailability. This notion is further supported by the findings that overexpression or knockdown of TTP could coordinately alter cellular alpha-Vit E levels in PCa cells.
Antiproliferative efficacy of alpha-Vit E is correlated with its cellular bioavailability in PCa cells. Modulating the expression of the efflux or influx transporters could sensitize the growth inhibition efficacy of Vit E in prostate cancer cells.

Download full-text

Full-text

Available from: Shuyuan Yeh
  • Source
    • "Cytotoxicity assay was performed according to the protocol described in our previous publication [22]. To determine the IC 50 value, 6.0 × 10 4 MDA- MB-231, Ishikawa, SKOV-3, HEC-1-A, and OVCA429 cells were plated in triplicate in 5% CS-FBS DMEM in 24-well culture plates. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Estrogen and estrogen receptor (ER)-mediated signaling pathways play important roles in the etiology and progression of human breast, endometrial, and ovarian cancers. Attenuating ER activities by natural products and their derivatives is a relatively practical strategy to control and reduce breast, endometrial, and ovarian cancer risk. Here, we found 3-butoxy-1,8,9-trihydroxy-6H-benzofuro[3,2-c]benzopyran-6-one (BTB), a new derivative of wedelolactone, could effectively inhibit the 17-estradiol (E2)-induced ER transactivation and suppress the growth of breast cancer as well as endometrial and ovarian cancer cells. Our results indicate that 2.5 μM BTB effectively suppresses ER-positive, but not ER-negative, breast, endometrial, and ovarian cancer cells. Furthermore, our data indicate that BTB can modulate ER transactivation and suppress the expression of E2-mediated ER target genes (Cyclin D1, E2F1, and TERT) in the ER-positive MCF-7, Ishikawa, and SKOV-3 cells. Importantly, this BTB mediated inhibition of ER activity is selective since BTB does not suppress the activities of other nuclear receptors, including glucocorticoid receptor and progesterone receptor, suggesting that BTB functions as a selective ER signaling inhibitor with the potential to treat breast, endometrial, and ovarian cancers.
    Full-text · Article · Aug 2014 · BioMed Research International
  • Source
    • "For example , prostate cancer DU145 cells are less sensitive to 20‐mM a‐vitamin E or VES treatment. Consistently, the cellular amount of a‐vitamin E and VES in DU145 cells is much lower compared to that in other prostate cancer cells after a‐vitamin E/VES treatment (Ni et al., 2007). Therefore, the cell's uptake eYcacy might be one of the factors contributing to the growth inhibitory eYcacy of a‐vitamin E and VES. "

    Full-text · Article · Jan 2007
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer is the second most commonly diagnosed cancer and the third leading fatal cancer in American men. Comprehensive studies from human epidemiological studies, animal tumor models, and cellular molecular levels suggested that alpha-vitamin E and its derivatives possess remarkable chemopreventive and chemotherapeutic against prostate cancer. This chapter details the facts of alpha-vitamin E and its nonantioxidant functions in prostate cancer, focuses on the biological mechanisms for the alpha-vitamin E and its ester analogue, alpha-vitamin E succinate (VES), in prevention and therapy of prostate cancer, and raises specific questions that remain for intensive investigation in the future.
    Full-text · Article · Feb 2007 · Vitamins & Hormones
Show more